Investor Ideas Potcasts, Cannabis News and Stocks on the Move; Episode 492 (CSE: FTRP) (CSE: CURA) (TSX: WEED) (NYSE: CGC) (OTC: HEMP)
Delta, Kelowna, BC - November 6, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today's podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Investor Ideas Potcasts, Cannabis News and Stocks on the Move; Episode 492 (CSE: FTRP) (CDE: CURA) (TSX: WEED) (NYSE: CGC) (OTC: HEMP)
Today's podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today's podcast we will be looking at a few public announcements and these relate to current market trends created from new state legalization.
Field Trip Health Ltd. (CSE: FTRP), one of the leaders in the development and delivery of psychedelic therapies, announced today that it is in advanced stages of identifying potential sites for Field Trip Health centers to treat people in Oregon with psilocybin therapies following the passage of Measure 109.
Measure 109, which was approved by voters in Oregon on November 3, 2020, requires the Oregon Health Authority to create a licensing system that will create a regulated program for the cultivation of psilocybin-producing mushrooms and the provision of supervised psilocybin therapy, effectively creating the first legal market for psilocybin therapies in North America.
Field Trip, which has been cultivating twenty-five species and strains of psilocybin-producing mushrooms at its research facility at the University of West Indies (Mona) in Jamaica since January, also announced its intention to seek licenses for cultivation in the State of Oregon when regulations following from Measure 109 are established.
"Based on its geography and climate, Oregon is an ideal place for cultivation of psilocybin-producing mushrooms. But cultivation that meets all quality standards and analytical testing requirements is complex," said Marshall Tyler, Field Trip's Director of Research. "Our current cultivation research, which is focused on developing safety methods for microbial contamination, pesticides, mycotoxins, heavy metals, and analyzing tryptamine content from all psychoactive species at all stages of growth, positions us well to establish effective cultivation operations in Oregon and, subject to the regulations that are established, to be able to offer a wide variety of products and therapies to the people in Oregon."
Studies from institutions such as Johns Hopkins University, New York University and Imperial College London have demonstrated that psilocybin therapy, when performed by qualified professionals, can have profoundly positive effects on treating mental and emotional health challenges such as depression, anxiety, end of life distress and addiction. Similar studies have demonstrated that psychedelic therapies may also increase a person's creativity, empathy, openness to others viewpoints and regard for the environment and planet.
"From the earliest days at Field Trip, we built our business case on the belief that the psychedelic industry would develop on two parallel and complementary paths: one that would be purely medical for the treatment of diagnosed mental health conditions, and the other which would make psychedelic therapies available to a wider audience," said Ronan Levy, Executive Chairman of Field Trip Health Ltd. "The success of Measure 109 validates that belief, and positions us to be the clear leader in the emerging psychedelics industry. With Field Trip Health centers rolling out across North America delivering best-in-class psychedelic therapies, and our research on cultivation of psilocybe, we are extremely well-positioned to help Oregonians access best-in-class psilocybin therapies. And with our drug development work on FT-104, our novel psychedelic molecule, advancing ahead of schedule, we are also positioned to help extend the psychedelic renaissance to people around the world."
Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF), a leading vertically integrated cannabis operator in the United States, today announced a pair of planned asset divestitures in Maryland for a combined $31.5 million in total proceeds:
- Entering into Definitive documentation to sell Curaleaf's interests in HMS cultivation and processor for $27.5 million to TerrAscend Corp. ("TerrAscend") (CSE:TER, OTCQX: TRSSF)
- Closing of its sale of Cumberland, MD processor for $4.0 million
Curaleaf announced today the signing of a definitive agreement to sell its rights to the HMS Health LLC and HMS Processing LLC ("HMS") assets in Maryland to TerrAscend for a total consideration of $27.5 million. The HMS asset sale includes the divestiture of operations in a 22,000 square foot co-located cultivation and processing facility in Frederick, MD. The total consideration due to Curaleaf of $27.5 million includes $25 million in cash due at closing as well as a $2.5 million interest bearing Note due and payable to Curaleaf on April 30, 2022. The transaction is expected to close pending customary closing conditions, including regulatory approval by the Maryland Medical Cannabis Commission.
The completion of the HMS transaction will allow Curaleaf to move forward, subject to regulatory approval, with its proposed acquisition of Maryland Compassionate Care and Wellness, LLC ("MCCW"), which operates a 55,000 square foot co-located cultivation and processing facility in Taneytown, MD and a dispensary in Gaithersburg, MD under the Herbology brand.
Curaleaf also announced today the closing of its sale of Curaleaf Maryland, Inc., which holds a processing license in Cumberland, MD, for a total consideration of $4.0 million. This divestiture closed on November 1, 2020 and supports Curaleaf's strategy for optimizing its vertically integrated presence in Maryland.
Joseph Lusardi, Chief Executive Officer of Curaleaf, stated, "The asset sales we announce today will allow us to optimize Curaleaf's vertically integrated presence in Maryland within the regulation which limits operators to a single grow and single processor. Overall, the Maryland market continues to see impressive growth with over 115,000 certified cannabis patients. The actions we are taking aim to further strengthen Curaleaf's position as a leading cannabis operator in Maryland as well as reaffirm our commitment to best serving our customers across the state."
Canopy Growth Corporation (TSX:WEED) (NYSE:CGC), a world-leading diversified cannabis, hemp, and cannabis device company, announced the launch of Quatreau, a new line of premium CBD-infused beverages. The naturally flavoured sparkling waters are Canopy Growth's first CBD-infused drinks, with both CBD-only and "balanced" (CBD + THC) offerings available in Canada. Launched on the heels of incredible growth in sales from the Company's THC-infused beverages, released earlier this year, Canopy Growth is uniquely positioned to win market share in the CBD beverage space.
"We are proud to debut our first CBD-infused beverage brand in Canada, where we already lead the cannabis-infused beverage category, at a price point that delivers both quality and value to consumers," said David Klein, CEO, Canopy Growth. "We created Quatreau as an alternative to sugary, caffeinated beverages or even alcohol. With both CBD-only and "balanced" (CBD + THC) offerings in four natural flavours, Quatreau meets the needs of discerning cannabis consumers."
Canopy Growth plans to continue developing category leading brands that are driven by consumer insights, product-focused, with industry leading scientific formulation. Building on the successful launch and strong sales of THC-infused cannabis beverage brands Tweed, Houseplant and Deep Space, Canopy is poised to continue leading the cannabis space with the launch of Quatreau CBD-infused sparkling water, a consistent CBD product in a beverage format that is familiar to consumers.
Quatreau's naturally flavoured Canadian product line includes four offerings named:
- Quatreau Cucumber + Mint (contains 20 mg of CBD and < 1 mg of THC)
- Quatreau Passion Fruit + Guava (contains 20 mg of CBD and < 1 mg of THC)
- Quatreau Ginger + Lime (contains 2 mg of CBD and 2 mg of THC)
- Quatreau Blueberry + Acai (contains 2 mg of CBD and 2 mg of THC)
Canopy was also among this week's large LP winners when it came to the markets, trading up nearly 5% over the past three days and joining other winners such as Aurora Cannabis (TSX: ACB) (NYSE: ACB), which traded up nearly 70% over the past three days, Aphria Inc. (NASDAQ: APHA) (TSX: APHA), trading up 5% and Tilray Inc. (NASDAQ: TLRY) which traded up nearly 30%.
Hemp, Inc. (OTC: HEMP) a global leader in the industrial hemp industry with bi-coastal processing centers, announced praise of five states that will now legalize marijuana for recreational and/or medical use.
Bruce Perlowin, CEO of Hemp, Inc., 55-year veteran of the marijuana industry, now known as the King of Hemp says, "Marijuana is coming full circle, but legally now. Back in my heyday, I was (and still) widely known as the King of Pot so it's interesting to see how things have progressed over the years and exciting to see where we'll be in the future."
"Hemp, Inc. is planning to launch a new division, Medical and Recreational Marijuana," says Perlowin. Thus far, there are no firm plans on what direction the Company will take in this new planned division since the opportunities are so vast. According to Perlowin, he will evaluate all the lucrative, potential opportunities and make a decision on how the company will enter the cannabis market in 2021.
"We may wait until full federal legalization. Once marijuana is fully legalized across the country, I think banks and merchant account providers will be more open and accepting of marijuana companies. Right now, the banking regulations for marijuana companies are very draconian. I've known so many banks to close accounts merely because they were associated with the industry. Anyway, we don't know if we'll wait for full legalization yet but that decision won't discount the building out of facilities and preparation for it. After legalization occurs and large scale marijuana grows are underway, we would already be positioned as a 'go-to' consultant due to our industry expertise."
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining the AI Eye.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Cannabis Social Media
Download our Mobile App for iPhone and Android